The Pfizer vaccine has been shown to be more effective against Covid than the AstraZeneca/Oxford jab, which elicits a stronger T-cell response. But a T-cell vaccine could be used to complement other jabs, he said, as T-cell vaccines might be more impervious to virus mutations. Rademacher and his team settled on tiny gold particles coated in peptides (bits of proteins) designed to generate the T-cell response in the body. Emergex is testing another T-cell vaccine against dengue fever on humans in a separate Swiss trial, with initial results due in January. The firm also wants to deploy its T-cell vaccines against influenza, Zika, Ebola and other infections.

Source: The Guardian November 15, 2021 12:45 UTC